This article was generated by an automated content engine and was reviewed by a human editor prior to publication. For additional information, read Aligos Therapeutics’s 8K filing here.
Aligos Therapeutics Company Profile
Aligos Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of novel therapeutics to address unmet medical needs in viral and liver diseases. Its drug candidate, ALG-055009, a small molecule THR-ß agonist that is in the Phase 2a clinical trial for the treatment of non-alcoholic steatohepatitis (NASH).
Read More
- Five stocks we like better than Aligos Therapeutics
- Differences Between Momentum Investing and Long Term Investing
- California Resources Stock Could Be a Huge Long-Term Winner
- Stock Analyst Ratings and Canadian Analyst Ratings
- Observability Wars: Datadog and Dynatrace Vie for Data Dominance
- What Are Dividend Challengers?
- Airbnb Stock Attracts Attention With Strong Cash Flow Strategy
